Phase 3 N=74 Micronutrient Supplementation in Patients With Heart Failure
Heart Failure
Primary: Left Ventricular Ejection Fraction — 44.7; 38.9; 44.9; 38.6 percentage of LVEF
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=438 Interventions to Improve Specialty Medication Adherence
Adherence, Medication · Nonadherence, Medication
Primary: Median Proportion of Days Covered (PDC) at 8-months Post-enrollment — 0.94; 0.88 proportion of days covered (PDC) — p=0.001
N/A N=227 Can Service Dogs Improve Activity and Quality of Life in Veterans With PTSD?
Post Traumatic Stress Disorders
Primary: World Health Organization Disability Assessment Scale II (WHO-DAS 2.0) Total Score — 38.31; 35.78; 41.76; 38.76 score on a scale — p=0.052
Phase 1 N=16 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
Obesity
Primary: Area Under the Plasma Concentration-time Profile From Time 0 to Last Quantifiable Concentration (AUClast) of Rosuvastatin in Periods 1, 4 and 7 — 35.17; 72.15; 100.90…
Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
N/A N=38 Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
Musculoskeletal Infection · Acute Hematogenous Osteomyelitis · Septic Arthritis
Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants
N/A N=11,545 Bariatric Surgery and COVID-19
COVID-19 · Bariatric Surgery Candidate
Primary: Revisions — 746; 316 Participants
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 2 N=99 A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
Diabetic Macular Edema
Primary: Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS)…
N/A N=37 Intermittent Fasting Adherence and Self Tracking
Hypertension · Obesity
Primary: Adherence to the Intermittent Fasting Regimen, Captured Via Daily Text Message, Over 18 Weeks, Expressed in Days Per Week — 4.7; 5.4 days per week
Phase 3 N=52 Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Bardet Biedl Syndrome (BBS) · Alström Syndrome (AS)
Primary: Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort — 32.3 percentage of…
N/A N=4,055 DIA_CENTRAL:T2D Treatment Pattern in Central Europe
Diabetes Mellitus, Type 2
Primary: Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist — 815; 1073; 78…
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
Influenza
Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants
Phase 2 N=44 Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Parkinson's Disease · Constipation
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events. — 9; 16; 1 Participants